INTRODUCTION
The complexity of the mammalian lipidome reaches to thousands of unique structures whose synthesis and localization are regulated by hundreds of different enzymes. Even though the molecular diversity of lipids approaches that of other biomolecules such as proteins, we have a much narrower understanding of their involvement in biological processes. One of the reasons for this gap in knowledge emerges from the fact that tools to study lipids in living systems are rather limited, especially when it comes to studies at the molecular level (Muro et al., 2014) . Advances in high-resolution mass spectrometry (MS) over the last few decades have significantly boosted our ability for such analyses even in complex matrices such as cellular extracts . Using these strategies, accumulating evidence links the global changes in lipid composition to complex cellular processes such as cell division, immune response, and insulin resistance (Atilla-Gokcumen et al., 2011 Koberlin et al., 2015; Yore et al., 2014) .
Apoptosis, a form of programmed cell death, is accompanied by numerous membrane-related morphological changes such as plasma membrane blebbing and disintegration of cell fragments to apoptotic bodies (Elmore, 2007) . Some lipid-specific studies have linked sphingolipids to apoptosis and have suggested a functional role (Dobrowsky et al., 1993; Lee et al., 2011; Mullen et al., 2012; Obeid et al., 1993; Zhang et al., 2015) . Others have analyzed lipid families and have reported changes in their composition during apoptosis (Li and Yuan, 2011; Wang et al., 2009) . These previous studies have provided valuable data, but did not look at specific lipid species in an unbiased, global lipidome framework. Using mass spectrometry-based global lipid profiling (Saghatelian et al., 2004) , we report here that specific ceramides, dihydroceramides, and sphingomyelins constitute the majority of the lipids that change during staurosporine-induced apoptosis. In addition, our results suggest that the accumulation of these lipids is strongly regulated in a lipid-specific manner. Finally, we present evidence that these changes are specific to apoptosis in cancer cells.
RESULTS

Significant Changes in Lipid Composition during Apoptosis
To analyze the changes in the lipidome during apoptosis, we used a cell line model. Specifically, we induced apoptosis using staurosporine in a human colorectal carcinoma cell line, HCT-116. Staurosporine inhibits a wide range of kinases in an ATP-competitive manner, and induces apoptosis in various cancer and non-cancer cells (Tanramluk et al., 2009 ). We conducted a time series experiment in staurosporine-treated cells whereby we measured cell viability and apoptotic activity ( Figure S1 ). Based on these results, we chose 0.3 mM staurosporine treatment for 5 and 16 hr to study the global changes in lipid composition over time ( Figure S1 ). Representative apoptotic and control cells are shown in Figure 1A . We collected staurosporine-treated and untreated cells and extracted their lipids. The lipid content was normalized based on protein concentration and internal standards (Table S1 ). Next, we performed liquid chromatography-mass spectrometry (LC-MS)-based profiling of the lipid extracts to study the changes in composition during apoptosis. Initially, to test whether the lipid composition changes during apoptosis, we comparatively analyzed the lipid profiles of treated (apoptotic) and non-treated (control) cells using principal-component analysis (PCA). PCA of lipid profiles showed two distinct clusters, one corresponding to control and 5-hr staurosporine-treated cells and the other corresponding to 16-hr staurosporine-treated apoptotic cells, suggesting that there are significant changes in lipid composition during apoptosis ( Figure 1B ).
Ceramides, Dihydroceramides, and Sphingomyelins Constitute the Majority of the Changes in Lipid Composition during Apoptosis
We next wanted to identify which specific lipids changed during staurosporine-induced apoptosis because these species could be involved in apoptosis. We conducted ANOVA and then focused on the species that show both significant differentiation (p % 0.05) and R3-fold change in any of the experimental conditions across three independent profiling experiments (n = 5 for each independent profiling experiment). Based on these criteria, we identified 16 lipid species that change significantly during staurosporine-induced apoptosis in . The majority of these species (14 of 16) belonged to the sphingolipid family. Specifically, nine ceramides/dihydroceramides, four sphingomyelins/dihydrosphingomyelins, a hexosylceramide, and an acylcarnitine and a fatty acid derivative accumulated during apoptosis (Table 1 and Figure 2 ).
There are more than 200 unique ceramides and dihydroceramides in the mammalian lipidome (Hannun and Obeid, 2011) . This structural diversity is mostly achieved by the modifications of the sphinganine or sphingosine backbone (shown in Figure 2 ) with fatty acids having different lengths (e.g., C14 versus C18) and saturation states (e.g., C18:0 versus C18:2). All sphingolipids we identified showed accumulation 16 hr after treatment. However, the level of accumulation and their progression over time were different: C16:0-, C16:1-, and C24:1-ceramide showed a slight depletion at 5 hr (Table 1 , denoted by Y), followed by a profound increase at 16 hr of treatment compared with control cells (Table 1) . The fine-tuning of individual ceramide and dihydroceramide levels is surprising: C16-dihydroceramide, which differs from C16-ceramide with one double bond on the sphingosine backbone, accumulated as apoptosis progressed, whereas C16-ceramide first showed depletion followed by a profound accumulation, suggesting these species are regulated differently.
We were intrigued by the fact that among thousands of different lipids present in our samples, accumulation of sphingolipids constituted almost 90% of the changes. Complementary to untargeted profiling, we analyzed the levels of $85 lipids from other major lipid families (fatty acids, glycerolipids, glycerophospholipids, and sterols) and found that there was no significant accumulation or depletion of these lipids during apoptosis (Table S2 ). Our findings suggest that significant changes in lipid composition occur at the level of specific lipid species (e.g., C16-ceramide), rather than at the level of lipid family (e.g., all ceramides). Almost all the significant changes are accumulation of members of a single lipid family, sphingolipids, (B) PCA of 16-hr staurosporine-treated (blue), 5-hr staurosporine-treated (red), and control (black) HCT-116 cells. We observed distinct clustering among 16-hr staurosporine-treated and the other two conditions without any a priori input, suggesting major global changes in lipid composition after 16 hr of treatment. PCA plot was generated in MPP 12.6.1 (Agilent Technologies). in staurosporine-induced apoptosis in HCT-116. Our multi-timepoint experimental setup and high-resolution MS analyses that enable the comparison of different sphingolipid structures allowed us to observe these differences in specific ceramides and dihydroceramides.
The significant changes in specific ceramides and dihydroceramides led us to study other sphingolipids. Ceramides and dihydroceramides can be converted to more complex sphingolipids such as sphingomyelins and sugar-modified ceramides ( Figure 3 ) through a tightly regulated biosynthetic pathway (Levy and Futerman, 2010; Mullen et al., 2011b) . We systematically targeted ceramides, dihydroceramides, sphingomyelins, dihydrosphingomyelins, and hexosylceramides, and calculated fold changes of different fatty acyl chain-containing (C14-C26) species. All of these species, except for hexosylceramides, showed accumulations at 16 hr after staurosporine treatment but at different levels. C22-ceramide showed the strongest accumulation, $14-fold, compared with other shorter acyl chain-containing ceramides. Similarly, C14-C20 dihydroceramides accumulated $10-fold (Table S3 ). Sphingomyelins and dihydrosphingomyelins showed moderate accumulations ($1.5-to 5-fold) compared with ceramides and dihydroceramides (Table S3) . We also detected elevated C14-and C16-ceramide and -dihydroceramide levels in the growth media of apoptotic cells compared with control cells, suggesting that these molecules are excreted to the extracellular matrix (Table S4 ). Together with the targeted analysis of lipids from different families, our global lipid profiling provided new information on the differential changes in ceramide and dihydroceramide composition, and support lipid-specific regulations during apoptosis.
To elucidate whether the ceramide accumulation we observe during apoptosis in HCT-116 cells is specific to staurosporine treatment or a consequence of apoptotic activity, we also studied ceramide levels in doxorubicin-induced apoptosis. Doxorubicin is a DNA intercalator, and is commonly used to induce apoptosis in wide range of cancers (Tacar et al., 2013) . We induced apoptosis in HCT-116 by doxorubicin treatment and performed targeted profiling of ceramides between treated and untreated cells (for details see Supplemental Experimental Procedures). Similarly to staurosporine treatment, ceramides and dihydroceramides showed significant accumulations (2-to 7-fold) in doxorubicin-induced apoptosis ( Figure  S2 ). These results support that accumulations of ceramides in staurosporineinduced apoptosis are not due to the staurosporine treatment per se, but rather to the apoptotic activity induced by staurosporine.
De Novo Ceramide Biosynthesis Is Activated during Staurosporine-Induced Apoptosis We observed a positive correlation between ceramide, dihydroceramide, and sphingomyelin accumulations. To investigate the regulatory mechanisms that lead to these changes, we explored the biosynthetic pathways involved in ceramide generation and their conversion to sphingomyelins. Ceramides can be synthesized via de novo biosynthesis, sphingomyelin hydrolysis by sphingomyelinases (SMases), or the salvage pathway , and are converted to sphingomyelins by sphingomyelin synthase (SMS) (Figure 3 ). Both increased SMase activity, especially acid SMase (aSMase), and the activation of de novo biosynthesis depending on stress conditions, contribute to apoptosis and result in elevated ceramide levels (Garcia- Barros et al., 2014; Ogretmen and Hannun, 2004; Testai et al., 2004; Wang et al., 2015) . We focused on de novo biosynthesis and the SMase activity-dependent degradation pathway, based on the positive correlation between ceramide and sphingomyelin accumulations (Figure 3 ).
Ceramides and dihydroceramides are synthesized from the N-acylation of sphinganine (shown in red in Figure 4A ) by ceramide synthases (CERSs). There are six CERSs (1-6) that synthesize ceramides with specific fatty acyl chains ( Figure 4A ) (Levy and Futerman, 2010) . Although transcriptional control of CERS genes is not completely understood, different apoptotic stimuli induce CERS expression (Mullen et al., 2012; Panjarian et al., 2008) . We measured the expression levels of CERS1-CERS6 in HCT-116 using Droplet Digital PCR (Pinheiro et al., 2012) . The expression levels of CERS2, CERS4, CERS5, and CERS6 enzymes, which synthesize ceramides that we found to accumulate during apoptosis, were significantly higher with staurosporine treatment ( Figure 4B ). This result suggests that accumulation of ceramides at the metabolite level can be explained by the increased expression of genes that are responsible for their biosynthesis. To test the SMase activity in apoptotic cells, we measured aSMase and neutral SMase (nSMase) activity in control and staurosporine-treated HCT-116. Surprisingly, both aSMase and nSMase activities were lower, whereas SMS activity did not change in apoptotic cells ( Figure 4C ). Decreased SMase activity could likely explain the elevated sphingomyelin levels we observed during apoptosis. Our results suggest that the accumulation of ceramides and dihydroceramides is due to de novo synthesis of ceramides followed by subsequent conversion of some of these ceramides to sphingomyelins, rather than the activation of the SMasedependent degradation pathway. These findings provide evidence of a complex biochemical regulation in which both ceramide and sphingomyelin levels are sustained at higher levels via increased de novo synthesis.
Differential Regulation of Sphingolipids in Non-Cancer Cells during Apoptosis
Previous studies have linked ceramide accumulation to apoptosis in cancer cells. However, the regulation of sphingolipids during apoptosis in non-cancer cell lines is underexplored. Tumorigenesis is accompanied by many metabolic alterations (Currie et al., 2013) ; thus, we hypothesized that there could be differences in sphingolipid regulation during apoptosis in cancer versus non-cancer cells. To test this, we analyzed the changes in lipid composition during staurosporine-induced apoptosis in colon fibroblasts, CCD-112CoN (referred to as CCD-112). We did not observe the accumulation of specific lipids outlined above in apoptotic CCD-112. In brief, we induced apoptosis in CCD-112 cells in a similar manner to that used for HCT-116 ( Figure S1 ) and conducted a systematic analysis of the changes in C14-C26 ceramides, dihydroceramides, sphingomyelins, and dihydrosphingomyelins. Strikingly, only C16-dihydroceramide accumulated R3-fold during apoptosis in CCD-112 (Table S3 ). To our knowledge these results suggest, for the first time, that the accumulation of sphingolipids in general, and ceramides in particular, is specific to colon cancer cells when compared with non-cancer colon cells. In a broader sense, this suggests ceramides as a potential biomarker to detect apoptosis in colon cancer cells, for instance to monitor therapeutic efficacy.
Staurosporine treatment causes apoptosis both in HCT-116 and CCD-112; however, sphingolipids accumulate only in HCT-116. We were intrigued by the difference in response to staurosporine treatment. To understand the origin of this, we collected untreated HCT-116 and CCD-112 cells, extracted lipids, and compared the levels of sphingolipids between the two cell lines (for normalization and the investigation of the matrix effect, see Supplemental Experimental Procedures and Table S1 ). We found that the levels of C14-, C16-, and C20-ceramides were similar, whereas C18-, C22-, C24-and C26-ceramides were slightly higher in CCD-112 ( Figure 5A , white bars). However, there was a profound difference in sphingomyelins: CCD-112 cells produce sphingomyelins at much higher levels than HCT-116 cells ( Figure 5A , gray bars). All the sphingomyelin species we looked at were higher, with C18-sphingomyelin showing a $35-fold increase in CCD-112. We also found that CERS2 and CERS5 were expressed at higher levels in CCD-112, concordant with the acyl chain-specific elevation of sphingomyelins in CCD-112 compared with HCT-116 ( Figure 5B ). Significant differences in lipid composition and metabolism in cancer (C) Activities of nSMase, aSMase and SMS were measured in control and apoptotic cells. There was a significant decrease in nSMase and aSMase, whereas SMS activity did not change during apoptosis. Data from three independent experiments (n = 15) are shown as means ± SD. (**p < 0.01; ***p < 0.001).
Figure 3. Simplified Scheme of Sphingolipid Biosynthesis
The scheme is modified from Wennekes et al. (2009) . De novo ceramide biosynthetic and sphingomyelin hydrolysis pathways are shown in red and green, respectively. Lipids that accumulate during staurosporine-induced apoptosis in HCT-116 are shown in red (dihydroceramides), blue (ceramides), and green (sphingomyelins). The expression levels of CERSs are higher in apoptotic cells. The activities of SMases are lower, whereas the activity of SMS does not change during apoptosis. cells have been reported (Eberlin et al., 2014; He et al., 2015; Menendez and Lupu, 2007; Zhang and Wakelam, 2014) . In the case of HCT-116 and CCD-112, decreased ceramide synthase expression in HCT-116 could be responsible for lower ceramide and sphingomyelin levels in this cell line compared with CCD-112.
Increased ceramide levels, either by exogenous addition or overexpression of the enzymes that synthesize these molecules, can lead to apoptosis; however, the involvement of dihydroceramides in apoptosis is controversial in different cell types (Casson et al., 2013; Lee et al., 2011; Osawa et al., 2005; Siddique et al., 2015; White-Gilbertson et al., 2009) . Previous studies have utilized exogenous delivery of ceramides to study phenotypic effects of increased ceramide levels in different systems (Dolgachev et al., 2003; Sentelle et al., 2012; Zeidan et al., 2008) . To test whether accumulation of these species is also responsible for apoptosis, we adapted similar protocols and carried out add-back experiments with C16-ceramide and C16-dihydroceramide in HCT-116 cells. We observed that exogenous addition of both species caused apoptosis; however, C16-ceramide showed a higher potency than C16-dihydroceramide at lower concentrations ( Figures 5C and S1 ). These results support that dihydroceramides also participate in apoptosis in cancer cells, similarly to ceramides.
Based on our lipid profiling results, C16-ceramide does not accumulate in apoptotic non-cancer CCD-112, unlike HCT-116. This surprising finding implies that the mechanisms by which ceramides contribute to apoptosis may be different in HCT-116 and CCD-112 cells. To investigate this, we carried out a similar add-back experiment with C16-ceramide and C16-dihydroceramide in CCD-112 and compared the results with HCT-116. Exogenous addition of 0.1 mM C16-ceramide caused apoptosis in HCT-116 ( Figures 5C and S1 ). On the contrary, there was no decrease in cell viability in CDD-112 under these conditions ( Figure 5D ). This is concordant with our prediction based on lipid profiling that ceramides are differentially regulated during apoptosis in cancer versus non-cancer cells, and suggests that CCD-112 displays an enhanced resistance to ceramide-induced apoptosis compared with HCT-116.
Lower toxicity of staurosporine in HCT-116 might suggest a potential chemoprotective role of ceramide accumulation against apoptosis, despite the current view of pro-apoptotic activity of ceramides (Ogretmen and Hannun, 2004) . We further explored this by testing the antagonism between staurosporine and a ceramide. In brief, we co-treated HCT-116 with staurosporine and C16-ceramide and compared the viability with that of only staurosporine-or C16-ceramide-treated cells. The cotreatment caused a greater decrease in cell viability (48%) compared with staurosporine (82%) and ceramide (87%) treatments alone ( Figure S3 ). This excludes the chemoprotective effect of C16-ceramide during staurosporine-induced apoptosis in HCT-116, and suggests a synergistic relationship between staurosporine and C16-ceramide.
Cancer Cell-Specific Accumulations of Ceramides and Dihydroceramides during Staurosporine-Induced Apoptosis Cancer cell lines exhibit diverse phenotypes and backgrounds, but frequently share common metabolic abnormalities (Currie et al., 2013) . To test whether a similar differential regulation of ceramides and dihydroceramides exists in other cell types, we induced apoptosis in cervical carcinoma (HeLa S3), breast adenocarcinoma (MCF-7), and non-cancerous retinal epithelial (RPE-1) cell lines ( Figure S1 ) and analyzed the changes in sphingolipid composition. Indeed, the changes we observed in HeLa S3 and MCF-7 were similar to those in HCT-116 during apoptosis. Specifically, C14-, C22-, and C24-ceramide and all the dihydroceramides we investigated (C14-C22) accumulated at least $3-fold in both HeLa S3 and MCF-7 cells. On the contrary, in apoptotic RPE-1 cells, none of the sphingolipids showed accumulations during apoptosis (Table S5) . These results support our conclusion that accumulation of specific ceramides and dihydroceramides in HCT-116 during apoptosis is a cancer-specific phenomenon. An important next step is to identify the genetic and metabolic basis of this specificity at the molecular level. ]. Abundance is the total ion count for a given ion. Lipid composition is normalized based on protein concentration and internal standards. CCD-112 cells produce similar levels of ceramides but higher levels of sphingomyelins compared with HCT-116. Dotted line indicates no difference (fold difference = 1). Data from two independent experiments (n = 10) are shown as means ± SD. (B) Expression levels of CERS2, CERS4, CERS5, and CERS6 were compared in HCT-116 and CCD-112 cells. mRNA levels of CERS2, CERS4, CERS5, and CERS6 were measured and normalized based on the expression level of HRPT1. CCD-112 expresses significantly higher levels of CERS2, CERS4, and CERS5. Data from three independent experiments (n = 9) are shown as means ± SD. *p < 0.05, **p < 0.01. (C) Cell viability in HCT-116 after C16-ceramide (white bars) and C16-dihydroceramide (gray bars) treatment. Data from three independent experiments (n = 15) are shown as means ± SD. (D) Cell viability in CCD-112 after C16-ceramide (white bars) and C16-dihydroceramide (gray bars) treatment. Data from three independent experiments (n = 15) are shown as means ± SD.
DISCUSSION
The role of ceramide accumulation either by exogenous addition, activation of SMases, or de novo synthesis during apoptosis is firmly established (Bose et al., 1995; Charles et al., 2001; Haimovitz-Friedman et al., 1994; Herr et al., 1997; Wang et al., 2015) . It has been proposed that ceramides interact with mitochondrial membrane proteins (Zhang et al., 2015) and cause changes in mitochondrial membrane potential (Sentelle et al., 2012) . In addition, ceramide accumulation either by exogenous addition or overexpression of CERSs and sphingomyelinase sensitize cancer cells to apoptosis (Testai et al., 2004; White-Gilbertson et al., 2009 ). Mullen et al. (2011a) showed CERS-dependent accumulation of ceramides and dihydroceramides in UV light-induced apoptosis in MCF-7. However, studies on the involvement of specific ceramides, dihydroceramides, and other ceramide analogs during apoptosis are still under way (Siddique et al., 2015; Zhang et al., 2015) . Using untargeted lipidomics whereby we analyzed the full lipidome, we identified ceramides, dihydroceramides, and sphingomyelins as the major lipids that change in staurosporine-induced apoptosis in HCT-116. Our results suggest that specific ceramides and dihydroceramides are regulated actively but differentially in apoptosis, and thus potentially have distinct involvements.
We found that ceramides and dihydroceramides accumulate during apoptosis in multiple cancer cell lines (HCT-116, MCF-7, and HeLa S3) but not in non-cancer cell lines (CCD-112 and RPE-1). This observation suggests that sphingolipid regulation differs between non-cancer and cancer cells during apoptosis. Our results are concordant with the culminating evidence that while different cancer cells display a large diversity in their metabolic activity, they often share characteristic alterations in their lipid metabolism (Currie et al., 2013) . Further analysis in a tissue-matched cancer (HCT-116) and non-cancer (CCD-112) cell line pair showed that the levels of ceramides and sphingomyelins, as well as the expression of different CERSs, are higher in pre-apoptotic non-cancer cells compared with cancer cells. Based on this observation, we argue that pre-apoptotic metabolite and expression levels between noncancer and cancer colon cells may explain why these cells respond differently to apoptosis.
Our high-resolution analysis of different cancer cell lines during apoptosis revealed slight variations in the specific lipids that accumulate, leading us to conclude that ceramides and dihydroceramides are regulated at the molecular level during apoptosis in cancer cells. For example, in HCT-116 C16-, C18-, C22-ceramide and -dihydroceramide; in HeLa S3 and MCF-7 C18-22 ceramides and -dihydroceramides show the strongest accumulations. Differences in expression levels of CERSs depending on the tissue type have been reported here and by others. CERS2 and CERS6 are highly expressed in HCT-116 ( Figure 5B ) and MCF-7 (Mullen et al., 2011b) ; CERS2, CERS5, and CERS6 show similar expressions in HeLa cells (Mesicek et al., 2010) . This tissue-dependent expression of CERSs could likely explain the different profiles of ceramide accumulation we observed in different cancer cells. Indeed, Mullen et al. (2011b) showed the complex counter-regulation of sphingolipids depending on the expression levels of different CERSs. As such, our observation is concordant with recently accumulating evidence regarding the somatic genetic variation in cancer cells, which leads them to develop novel biological responses to different stimuli (Vogelstein et al., 2013) , and systematic changes in lipid composition in cancers compared with adjacent tissues due to tumor microenvironments (Guo et al., 2014) .
We also present evidence that ceramides are potential biomarkers of apoptosis in colon cancer cells. Lipids have been suggested as biomarkers in different cancers (Fernandis and Wenk, 2009) . A recent phase II clinical trial associated increased ceramide levels in serum in a subgroup of patients with chemotherapy response (Saddoughi et al., 2011) . We found colon cancer cell-specific accumulations of ceramides in the growth media of apoptotic cells. Taken together, we present ceramides and dihydroceramides as potential biomarkers to evaluate the apoptotic activity in colorectal carcinoma, for example while monitoring drug efficacy.
Ceramides can display unique physiological properties and act as second messengers to extracellular stimuli such as growth factors, chemical agents, and irradiation (Bose et al., 1995; Huang et al., 2011; Ogretmen and Hannun, 2004; Perera et al., 2012; Pettus et al., 2002; Senkal et al., 2010) . There are more than 200 structurally distinct ceramides with unique modifications. This structural diversity within ceramides is due to more than 28 enzymes involved in the metabolism of these molecules. This ''many ceramides'' paradigm suggests that individual ceramide species are regulated differently and have distinct functions (Hannun and Obeid, 2011; Kroesen et al., 2001; Mullen et al., 2011a; White-Gilbertson et al., 2009 ). Our results strongly support this paradigm. While the origins and biological implications of these accumulations remain largely unknown, we made a first step by showing that there are changes at the molecular level in ceramide and dihydroceramide composition during staurosporine-induced apoptosis that are specific to cancer cells. We expect that integrative approaches exemplified here that combine comparative lipidomics in cancer and non-cancer cells and biochemical characterizations will help to elucidate the involvement of unique lipid structures in apoptosis.
SIGNIFICANCE
Using a comparative lipidomics approach, we showed that specific ceramides, dihydroceramides, and sphingomyelins constitute the majority of the changes in lipid composition during staurosporine-induced apoptosis in HCT-116. Interestingly, we observed these changes only in cancer cells. Some ceramides and dihydroceramides not only accumulate in these cells but are also excreted to the extracellular environment during apoptosis. Taken together, our results suggest that ceramides are potential biomarkers of apoptosis in cancer cells. The role of ceramides in apoptosis is firmly established; however, our multi-time-point analysis of the change in lipid composition, combined with highresolution MS, provides insights into how specific ceramides and dihydroceramides exhibit dynamic changes as apoptosis progresses, providing evidence for regulation of these structures at the specific lipid level.
EXPERIMENTAL PROCEDURES
Detailed information on the materials used can be found in Supplemental Experimental Procedures, as well as detailed procedures for cell culture and LC-MS methods.
Preparation of Lipid Extracts, LC-MS Method, and Data Analysis
Lipid preparation and the LC-MS method were adapted from Saghatelian et al. (2004) . Lipids were extracted following a variation of the Folch method (Folch et al., 1957) . In brief, pellets were resuspended in 1 ml of PBS from which 30 ml was taken and lysed to measure the protein concentration. The rest of this solution was transferred to a glass Dounce tissue grinder to which 1 ml of MeOH and 2 ml of CHCl 3 were added. The homogenate was transferred to a glass vial and centrifuged. The organic layer was then carefully removed and dried under vacuum. Samples were normalized based on protein concentration and resuspended in chloroform.
LC-MS acquisition was performed using an Agilent 1260 HPLC and an Agilent 6530 Series Accurate-Mass Quadrupole Time-of-Flight mass analyzer (Agilent Technologies). In negative mode, a Gemini C18 reversed-phase column (5 mm, 4.6 mm 3 50 mm) and a C18 reversed-phase guard cartridge were used for separation in the LC method. In positive mode LC separation was achieved using a Luna C5 reversed-phase column (5 mm, 4.6 mm 3 50 mm) along with a C5 reversed-phase guard cartridge. Measurement of aSMase, nSMase, and SMS Activity Assays were adapted from previous protocols (Chen et al., 2013; Shah et al., 2008) . Control and staurosporine-treated cells were collected and lysed by sonication (10 s 3 3) in buffer supplemented with EDTA-free protease inhibitor (Roche) and phosphatase inhibitor cocktail 2 (Sigma). Neutral buffer (25 mM Tris [pH 7.5], 12 mM MgCl 2 ) and acidic buffer (100 mM NaAc [pH 5.0], 0.1% Triton X-100) were used in nSMase/SMS and aSMase assays, respectively. For each assay, 100 mg of protein in $30 ml were mixed with lipid standards and the mixture was incubated at 37 C for 3 hr. Reactions were quenched by adding 600 ml of MeOH. Afterward, the samples were centrifuged, dried under vacuum, and resuspended in 100 ml of MeOH. Droplet Digital PCR Total RNA was extracted from HCT-116 and CCD-112 cells using the RNeasy Mini Kit (Qiagen). RNA quality and yield were assessed by gel electrophoresis and a Nanodrop-1000 spectrophotometer. cDNA was obtained by reverse transcription using the iScript cDNA Synthesis kit (Bio-Rad) as per manufacturer's instructions. Reaction mixtures were prepared by combining the Droplet Digital PCR Supermix (Bio-Rad), primers and probes and DNA sample according to Bio-Rad's protocol for the Droplet Digital PCR QX200 System. A full description of the procedure and the primers used can be found in Supplemental Experimental Procedures. The graphs were generated in GraphPad Prism version 5.00.288.
Ceramide Add-Backs After 24 hr of seeding, cells were treated with different concentrations of C16-ceramide and C16-dihydroceramide for 16 hr. Concentrations of C16-ceramide and C16-dihydroceramide were prepared prior to additions in ethanol/dodecane 98:2 (v/v). The final concentration of ethanol/dodecane was 0.5% (v/v). After treatment, cell viability was evaluated by the MTT assay. The co-treatment of C16-ceramide and staurosporine was carried out similarly except that the final concentration of organic solvent in the assay was 0.6% (ethanol/dodecane/DMSO).
Viability Assay
Cell viability was evaluated by the MTT assay based on the ability of viable cells to convert a tetrazolium salt into a purple formazan product insoluble in water. A full description of the MTT assay can be found in Supplemental Experimental Procedures. The graphs were generated in GraphPad Prism version 5.00.288. Figure S1 . Viability assay for colon cell lines and PARP cleavage in non-cancerous and cancerous cell lines (related to Figure 1A , Figure 5C and Supplemental Experimental Procedure "Cell culture and treatments"). S2 Figure S2 . PARP cleavage and ceramide/dihydroceramide fold changes in HCT-116 cells after doxorubicin treatment (related to Table 1 ). S3 Figure S3 . Effect of staurosporine and C16-ceramide combination treatment on viability of HCT-116 cells (related to Figure 5C ). S4 Table S1 . Matrix effect and quantification of ceramides in HCT-116 and CCD-112 cells (related to Figure 5A and Experimental Procedure "Preparation of Lipid Extracts, LC-MS Method and Data Analysis" and Supplemental Experimental Procedure "Normalization and the matrix effect" and "Quantification of ceramides by LC-MS"). S5 Table S2 . Targeted analysis of lipids during apoptosis in HCT-116 cells (related to Figure 2) . S6 Table S3 . Targeted analysis of ceramides, dihydroceramides, sphingomyelins and dihydrosphingomyelins during apoptosis in non-cancerous (CCD-112) and cancerous (HCT-116) colon cell lines (related to Figure 5A and Figure 5B ). S7 Table S4 . Targeted analysis of ceramides and dihydroceramides released into the culture media during apoptosis in HCT-116 (related to Figure 3 and Supplemental Experimental Procedure "Media extraction"). S8 Table S5 . Targeted analysis of ceramides and dihydroceramides during apoptosis in non-cancerous (RPE-1) and cancerous (HeLa S3 and MCF-7) cells (related to Figure 5A ). S9
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Supplemental References S16 S2 Figure S1 . Viability assay for colon cell lines and PARP cleavage in non-cancerous and cancerous cell lines (related to Figure 1A , Figure 5C and Supplemental Experimental Procedure "Cell culture and treatments"). Figure 5C ).
MTT assay was performed to determine the viability of HCT-116 cell line treated with either staurosporine (0.1 µM) or C16-ceramide (0.1 µM) or in combination of both compounds for 16 hours. Data from two independent experiments (n = 10) are shown as mean ± SD. Table S1 . Matrix effect and quantification of ceramides in HCT-116 and CCD-112 cells. 13 C 18 -Oleic acid and C17-Ceramide were used as internal standards in matrix effect evaluation a (related to Figure 5A and Experimental Procedure "Preparation of Lipid Extracts, LC-MS Method and Data Analysis" and Supplemental Experimental Procedure "Normalization and the matrix effect" and "Quantification of ceramides by LC-MS"). Figure 5A and Figure 5B ).
CCD-112
HCT - Abundance is the total ion count for a given ion. Each ion corresponds to a mass-to-charge ratio (m/z), which is used to assign the lipid species.
e Not detected. Abundance is the total ion count for a given ion. Each ion corresponds to a mass-to-charge ratio (m/z), which is used to assign the lipid species.
S8
d Not detected in control. Fold increase could not be determined due to the low abundance in control cells.
e Not detected. Table S5 . Targeted analysis of ceramides and dihydroceramides during apoptosis in non-cancerous (RPE-1) and cancerous (HeLa S3 and MCF-7) cells a-c (related to Figure 5A ). Cell culture and treatments. HCT-116, HeLa S3 and MCF-7 were grown in DMEM and CCD-112 cells in EMEM. RPE-1 cell line was grown in DMEM/F-12 50/50 containing 0.3% (w/v) sodium bicarbonate. All cell culture media were supplemented with 10% (v/v) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cell lines were maintained using standard incubation conditions at 37 °C and 5% CO 2 . Cells were treated at 70-80% confluency. Twenty-four hours after seeding, cells were exposed to different times and concentrations of staurosporine, doxorubicin, C16-ceramide or -dihydroceramide at 37 °C.
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Immunofluorescence and image acquisition. After 24 hours of seeding, cells were treated with 0.3 µM staurosporine. After treatment, the staining was carried out using the Apoptosis/Necrosis Detection Kit (ab176749, Abcam, Cambrigde, UK) following manufacturer's instructions. Images were acquired on a Leica DMI6000B inverted microscope using LAS AF software (Leica AF6000 Modular System, Leica Microsystems CMS GmbH, Germany).
LC-MS Method Data Analysis.
The flow rate was 0.1 mL/min for the first 5 min followed by a change to 0.5 mL/min for the remainder of the gradient. A DualJSI fitted electrospray ionization (ESI) source was used for MS analysis with a capillary voltage of 3500 V and fragmentor voltage of 175 V. Drying gas temperature was 350 °C with a flow rate of 12 L/min. Data was collected using an m/z range of 50-1700 in extended dynamic mode. Tandem mass spectrometry data were collected using the following collision energies: 15, 35, 55, 75, 95 eV for each m/z.
For untargeted lipidomics, raw data obtained was imported into MassHunter Profinder (version B.06.00, Agilent Technologies) for peak alignment. For each profiling experiment, five biological replicates for the three conditions (control, 5h, and 16 h) were used. Data from Profinder was imported into Agilent Mass Profiler Professional (MPP, version B12.6.1) for statistical analysis where species were filtered based on frequency (60%). We conducted ANOVA to determine statistically significant species and eliminated all features with p > 0.05. Next, species were compared in a pairwise manner using three independent profiling experiments and we focused on the species that changed at least three fold across three independent profiling experiments. The resulting compounds were then matched to METLIN database to identify a candidate molecule based on accurate mass (Tautenhahn et al., 2012; . Known lipid standards (or lipids belonging to same lipid families) were purchased for the candidate lipids. MS/MS fragmentation patterns of the species of interest and known candidate lipids were compared. While fragmentation patterns were investigated, searches based on MS/MS fragments provided in METLIN were used complementary to the fragmentation pattern of known standards. For targeted analysis, the corresponding m/z's for each ion were extracted in Agilent MassHunter Qualitative Analysis (version B.06.00). Peak areas for each ion were manually integrated and average abundances were calculated for each condition. Fold changes were subsequently calculated.
Droplet digital PCR (ddPCR).
Quantification was performed with probe-based assays using pre-designed Integrated DNA Technologies (IDT, Coralville, IA, USA) Primers and ZEN double-quenched probes. Water-in-oil emulsion droplets were generated using an Automated Droplet Generator (Bio-Rad) and transferred to 96-well plates, which were heat-sealed using foil sheets. Target genes and the reference gene, HPRT1 (hypoxanthine phosphoribosyltransferase 1) were amplified in parallel by thermal cycling the droplet emulsions as follows: 95 °C for 10 min (Taq DNA polymerase activation), 40 cycles of 94 °C for 30 s (denaturation), 56 °C for 60 s (annealing and extension) with a final 10 min inactivation step at 98 °C. The fluorescence of each thermally cycled droplet was measured using the QX200 droplet reader (Bio-Rad). Data was analyzed using the QuantaSoft software (Bio-Rad) after threshold setting on fluorescence of negative controls. Sequences of primers: CERS1 sense 5-GCC TTC CAC AAC CTC CTG-3, antisense 5-AAC TGG GTA ACA AGC AGA GTC-3; CERS2 sense 5-CAC TGC GTT CAT S11 CTT CTA CCA-3, antisense 5-GCT CTA TCC TGC CTT CTT TGG-3; CERS3 sense 5-ACA TCA AAG CCA AGT CTA AAT AAC AG-3, antisense 5-GGC TAT ATG ACT TAT GGG AGG TT-3; CERS4 sense 5-ACA TCA GAA GCC CGT TGA AG-3, antisense 5-CTC TTC CTC ATC TTC TCC TTT GTC-3; CERS5 sense 5-CCG ATT ATC TCC CAA CTC TCA A-3, antisense 5-GCC AAT TAT GCC AAG TAT CAG C-3; CERS6 sense 5-TGA CTC CGT AGG TAA ATA CAT AAA GG-3, antisense 5-CAA TCA GGA GAA GCC AAG CA-3; HPRT1 sense 5-TTG TTG TAG GAT ATG CCC TTG A-3, antisense 5-GCG ATG TCA ATA GGA CTC CAG-3.
MTT Assay. After treatment, the plates were centrifuged, the medium was removed and 200 µL of media with 9% MTT (5 mg/mL in PBS) were added to each well. The plates were subsequently incubated for 3 h at 37 °C. After incubation, 150 µL of media were removed from each well and 90 µL of DMSO were added to each well. Treatments were carried out at a minimum of triplicates. The absorbance was measured using an automatic plate reader (Spectra MR™, Dynex technologies, Inc., Chantilly, VA, USA) at 550 nm. Cell viability was calculated as percentages relative to control cells.
Western blot analysis. Cells and media were collected in falcon tubes and centrifuged. The supernatant was discarded and cells were washed with PBS, and centrifuged. Cells were lysed with M-PER reagent (Thermo Scientific, Rockford, IL, USA) containing a protease inhibitor cocktail (Roche Diagnostics Indianapolis, IN, USA); debris was then removed by centrifugation and supernatant used for measuring protein concentration by Bradford assay (Thermo Scientific, Rockford, IL, USA). Equivalent amounts of protein were separated on 10% SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Germany). Membranes were blocked with TBS-Tween [10 mM Tris-base, 100 mM NaCl, 0.1% Tween 20 (pH 7.5)] containing 5% nonfat dry milk, then washed with TBS-Tween and exposed to anti-PARP (PARP Rabbit Ab, Cell Signaling Technology, Danvers, MA, USA). After primary incubation, membranes were washed with TBS-Tween followed by incubation with anti-rabbit secondary antibody. Then, membranes were washed with TBS-Tween, and developed using the SuperSignal West Pico kit (Thermo Scientific, Rockford, IL, USA). Blots were stripped using stripping buffer [6.3 mmol/LTris-base, 0.2% SDS, 0.8 % (v/v) β-mercaptoethanol (pH 6.8)] and re-blotted for anti-tubulin in order to confirm equal protein loading.
Normalization and the matrix effect. Normalization across different samples was carried out based on protein concentration and the use of internal standards (Oleic acid-13 C18 and C17-ceramide). Ionization efficiencies based on total ion counts of the standards were investigated and corrected when necessary.
Quantification of ceramides by LC-MS.
A dilution experiment was performed with a non-endogenous ceramide to quantify ceramides in HCT-116 and CCD-112 cells. Prior to extraction, samples were spiked with C17-ceramide as an internal standard. After extraction, serial dilutions of the samples were performed. These samples were analyzed using LC-MS QTOF in negative ESI mode. The data acquisition conditions were similar to that of profiling experiments. A calibration curve was obtained based on the ion counts and different concentrations of C17-ceramide in HCT-116 and CCD-112 cells separately. In order to use C17-ceramide as a standard to calculate the concentrations of endogenous ceramides, equal concentrations of C14-, C17-, C16-, C22-and C24-ceramide were prepared, injected into LC-MS QTOF and ion abundances were calculated. Based on this, response factors that account for differences in ionization efficiency were determined for C14-, C16-, C22-and C24-ceramides. Subsequently, C14-, C16-, C22-and C24-ceramide were quantified.
Media extraction. The growth media of staurosporine-treated and untreated HCT-116 were collected from which lipids were extracted. Briefly, a mixture of media:MeOH:CHCl 3 (1:1:2) was vortexed and allowed to settle (the procedure was repeated three times per sample). The sample was then centrifuged and the organic layer recovered from which 6 mL were taken and dried under vacuum. Finally, all the samples were resuspended in 200 µL of chloroform. The experiment was carried out in triplicate.
